newsfilter
← Latest News
GlobeNewswire·

Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million ‒ ‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒ ‒ Conference Call